PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ascroatActa Stomatologica Croatica
 
Acta Stomatol Croat. 2017 September; 51(3): 240–247.
PMCID: PMC5708326

A Review of the Effectiveness and Side-Effects of Fluocinolone Acetonide 0.1% in the Treatment of Oral Mucosal Diseases

Abstract

Topical steroids have been widely used in the treatment of symptomatic oral lesions to reduce pain and inflammation. Potent topical steroids such as clobetasol propionate, fluocinolone acetonide (FA), and fluocinonide have been widely used in the treatment of severe oral mucosal lesions. Many reports have demonstrated that these steroids were effective in treating oral lesions with only minor side-effects. This review describes the effectiveness and side-effects of using FA 0.1% in the treatment of symptomatic oral lichen planus (OLP), oral lichenoid drug reaction (OLDR), oral pemphigus, and herpes associated erythema multiforme (HAEM). FA 0.1% was effective and safe in the treatment of patients with multiple systemic diseases and a pregnant patient with HAEM. Moreover, this topical steroid rapidly reduced pain, inflammation, and enhanced lesion healing with no serious side-effects other than pseudomembranous candidiasis, which is easily treated. In some cases, a long-term treatment with FA 0.1% resulted in hyperpigmentation at the areas of previously healed oral lesions; however, this hyperpigmentation was gradually resolved after discontinuing topical steroid treatment.

Key words: Candidiasis, Erythema Multiforme, Fluocinolone Acetonide, Lichen Planus, Lichenoid, Pemphigus

Introduction

Over the past decade, various treatments have been used to treat chronic or severe oral lesions, however, a complete cure is difficult to achieve. Topical steroids are considered to be the first-line therapy for oral autoimmune diseases. These drugs have been widely used in the treatment of symptomatic oral lesions, such as recurrent aphthous ulceration (1), oral lichen planus (OLP) (2, 3), oral lichenoid drug reaction (OLDR) (4), pemphigus (5-7), mucous membrane pemphigoid (MMP) (8), and Herpes Associated Erythema Multiforme (HAEM) (9). Topical steroids can be used alone or combined with systemic steroids in the treatment of severe oral mucosal diseases. Since topical steroids directly contact and penetrate through the mucous membrane of erosive/ulcerative oral lesions, they can enhance lesion healing (10).

Fluocinolone acetonide (FA) was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City, Mexico. FA is a synthetic hydrocortisone derivative primarily used to treat skin inflammation and relieve itching. The fluorine substitution at position 9 in the steroid nucleus ring greatly enhances its activity (11) (Figure 1). FA in orabase (FAO) or FA in solution (FAS) 0.1% can be used as an alternative treatment for recalcitrant oral lesions such as OLP, OLDR, pemphigus, and HAEM to reduce pain and inflammation. The present review discusses the effectiveness and side-effects of FAO/FAS in the treatment of symptomatic oral lesions. The use of FA as orabase (FAO) or solution (FAS) 0.1% in the treatment of various oral lesions is described.

Figure 1
Chemical structure of fluocinolone acetonide

Oral lesions that were treated using FA 0.1%

Oral lichen planus (OLP)

In 1985, topical steroid–FAS 0.1% was first prepared by the head of the Pharmacology and Oral Medicine Departments, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand, and later developed as FAO 0.1% in 1988 (12). FAO 0.1% was effective in the treatment of recalcitrant ulcerative OLP in a 36-year-old female (Figure 2a). Notably, the OLP lesions on her buccal mucosa showed nearly complete remission after 2 weeks of FAO 0.1% treatment (Figure 2b). Moreover, a 29-year-old female presented to the Oral Medicine Clinic with atrophic OLP on both buccal mucosae and these lesions were unresponsive to previous medications. After treatment with FAO 0.1%, the lesions on her buccal mucosa showed a gradual improvement until complete remission was seen at 22 months (Figure 3a, 3b). In addition, both FAO and FAS use resulted in improved results in the treatment of OLP during a 2 year-follow-up (13). However, in this study, FAO 0.1% was shown to be more effective compared with FAS 0.1%.

Figure 2
a Recalcitrant ulcerative OLP on the right buccal mucosa that was unresponsive to any medications. Figure 2b OLP lesion on the right buccal mucosa showing nearly complete remission after treatment with FAO 0.1% for 2 weeks.
Figure 3
a Atrophic OLP on the right buccal mucosa that was unresponsive to any medications. Figure 3b Lesions resolved after treatment with FAO 0.1% for 22 months.

Regarding the immunopathogenesis of OLP, we found that the proinflammatory cytokine TNF-α was expressed in every case of OLP in Thai patients, indicating that TNF-α plays an important role in the immunopathogenesis of OLP in Thai patients (14). After treating their OLP lesions with FAO 0.1%, the same lesions were re-biopsied to investigate their TNF-α expression. We found that FAO 0.1% inhibited TNF-α expression in every case. Therefore, FAO 0.1% reduced the OLP inflammatory process by inhibiting the expression of the proinflammatory cytokine TNF-α.

Oral lichenoid drug reaction (OLDR)

OLDR is a common lesion in Thai patients. The oral manifestations and histopathological features of this lesion are similar to those of OLP (15).The oral lesions in OLDR erupt after taking a specific drug and resolve after withdrawing the suspected drug. It is not difficult to diagnose and treat OLDR if a patient is taking only one drug (16). However, most patients take multiple drugs and it can be difficult to withdraw the suspected drug (17). Potent topical steroids can be used in the treatment of OLDR. A 72-year-old female patient with a history of cardiomegaly, hypertension, and diabetes mellitus developed severe OLDR after an insulin injection, with severe lesions erupting on her bilateral buccal mucosae. White striae and excessive bleeding were seen on her right buccal mucosa (Figure 4a). After withdrawing the type of insulin injected and replacing it with another type of insulin, her buccal mucosa returned to normal state within 6 months of FAO 0.1% treatment (Figure 4b). FAO 0.1% was found to be effective in rapidly reducing pain and enhancing lesion healing. This topical steroid formulation is also safe to use in treating patients with multiple systemic diseases (4).

Figure 4
a White striae and severe bleeding seen on the left buccal mucosa. Figure 4b After a treatment with FAO 0.1% and changing the type of insulin injected, the buccal mucosa returned to normal.

Oral Pemphigus

Pemphigus is a fatal autoimmune disease the oral manifestations of which typically precede its skin lesions. The gingiva is the first and most common site of the oral manifestation of pemphigus (18). Systemic steroids have been used in the treatment of oral pemphigus. However, when used in combination with topical steroids, systemic steroid doses can be reduced. A 35-year-old female patient presented to the Oral Medicine Clinic with severe pain and generalized desquamative gingival epithelium for one month (Figure 5a). One month after combined treatment with 40–60 mg/day prednisolone and topical FAS 0.1% three times/day on the gingiva, the lesions showed nearly complete remission (Figure 5b). Unfortunately, the patient subsequently developed Cushing syndrome: moon face, steroid acne, and hirsutism (Figure 6). Her physician gradually reduced the systemic steroid dose and her condition showed improvement. Interestingly, following long-term treatment of a 43-year-old male pemphigus patient with FAS 0.1% combined with 60 mg/day prednisolone, the oral lesions showed complete remission after 1 year (6). Moreover, his oral pemphigus lesions remained in complete remission during 12 years of follow-up without recurrence or any side-effects.

Figure 5
a Severe generalized desquamative gingival lesions in a patient with pemphigus. Figure 5b Pemphigus lesions on the gingiva showing nearly complete remission after treatment with prednisolone 40–60 mg/day and FAS 0.1% for 6 weeks.
Figure 6
Patient with pemphigus developed Cushing syndrome characterized by moon face, steroid acne, and hirsutism after treatment with a systemic steroid and FAS 0.1% for 6 weeks.

Herpes Associated Erythema Multiforme (HAEM)

HAEM is an uncommon lesion caused by herpes simplex virus infection and is rarely found in pregnant women (9). FAO and FAS 0.1% were effective in treating severe painful oral ulcerations in a 28-year-old pregnant patient with HAEM (9). Short-term treatment (2 weeks) with this potent topical steroid rapidly reduced pain with nearly complete lesion healing. FAO and FAS 0.1% were effective and safe in the treatment of HAEM in this pregnant patient, who gave birth to a healthy son. Moreover, FAO and FAS 0.1% are low cost and without any side effects in this case.

Side-effects of FAO/FAS

During the treatment of oral lesions such as OLP with FAO/FAS 0.1%, pseudomembranous a candidiasis eruption is common. White plaques that can be wiped off can develop on the buccal mucosa after treatment with FAS 0.1% (Figure 7a). However, pseudomembranous candidiasis is effectively treated with topical antifungal drugs (Figure 7b) (13, 19). In some OLP cases, long-term treatment with topical steroid-FAO 0.1% resulted in hyperpigmentation at the areas of previous oral lesions (Figure 8a). During the follow-up, the mucosal hyperpigmentation gradually resolved within 3 years after discontinuing this topical steroid (Figure 8b).

Figure 7
a Pseudomembranous candidiasis that developed after treatment with FAO for 1 month. Figure 7b after treatment with topical antifungal- miconazole gel, the buccal mucosa showed nearly complete remission.
Figure 8
a Hyperpigmentation on the right buccal mucosa after treatment with FAO 0.1% for 5 years. Figure 8b Hyperpigmentation on the right buccal mucosa gradually resolved within 3 years after discontinuing FAO 0.1% treatment.

Discussion

FA 0.1%, both in solution or orabase forms, has been used in the treatment of various recalcitrant oral mucosal diseases. Moreover, only minor side-effects such as pseudomembranous candidiasis or post-inflammatory hyperpigmentation were found with FA use in our long-term observation. FA can be used alone or combined with systemic steroids in the treatment of severe oral lesions in patients with multiple systemic diseases. Carrozzo et al. suggested that the combination of systemic steroids and high potency topical steroids results in good control of these oral lesions (8). This regimen has been found to be safe and effective with only minor side-effects during or after the treatment of oral lesions in both short-term and long-term follow-up. One study showed the transmucosal systemic absorption of potent topical steroids, such as clobetasol (20). Thus, careful monitoring of patients receiving corticosteroid therapy is recommended to avoid adverse local or systemic effects. However, some side-effects of potent topical steroids, including clobetasol propionate 0.05% and betamethasone, such as Cushing’s syndrome, have been reported (21).

In this review, FAS 0.1% in combination with 40–60 mg/day prednisolone for one month in the treatment of severe oral pemphigus resulted in Cushing’s syndrome. Therefore, the treatment of severe oral lesions with a systemic steroid should be carefully monitored and these lesions should be treated by an expert.

A report of an HIV patient with OLDR who had very painful erosive lesions involving the lip and buccal mucosa showed that this patient responded to topical FA 0.1% treatment (22). This topical steroid was effective, and alleviated the patient's oral pain. Interestingly, a report showed that potent topical steroids such as FA 0.1%, clobetasol propionate 0.05%, and dexamethasone 0.05% were effective in the treatment of severe oral lichenoid drug reaction (OLDR) lesions without serious side-effects in patients with multiple systemic diseases during a 7-year follow-up (4). However, the role of a specific drug in the pathogenesis of OLDR may be important because the drug acts as an antigen, triggering T-cells. Antigen-specific CD8+ cytotoxic T cells then secrete cytokines, such as TNF-α or interferon-α. These cytokines subsequently activate T cells and dendritic cells and trigger basal cell keratinocyte apoptosis, causing an inflammatory immune response (23, 24).

Regarding oral mucosal hyperpigmentation, one observation report suggested that mucosal pigmentation could be a secondary effect of topical tacrolimus treatment due to an increase in the number of melanocytes and to an increased melanin production (25). Histopathology from the mucosal pigmentation showed an increase in melanocyte numbers and melanogenesis. However, the hyperpigmentation disappeared when the treatment was stopped, which is similar to the OLP case treated with FA in this review.

In addition to its use on oral lesions, FA may have other applications. A study found that FA strongly potentiated the TGF-β-associated chondrogenesis of bone marrow mesenchymal stem/progenitor cells, increasing the levels of collagen type II more than 100-fold compared with the widely used drug, dexamethasone (26). Thus, FA/TGF-β3 may be clinically used to increase the efficiency of regenerative approaches based on the chondrogenic differentiation of stem cells. The effects of FA on reparative dentin formation and the recovery of injured dental pulp have also been reported (27). The results showed that FA promoted the proliferation of human dental pulp cells (DPCs), especially for the CD146+ subpopulation. CD146+ cells have been shown to be mesenchymal stromal cells capable of multilineage differentiation (28-30). Thus, in the injured pulp, an increase in CD146+ cells may provide cells that can differentiate into odontoblasts for repairing the dentin defect, as well as reconstituting the dental pulp cell population. Therefore, FA initiates mineralization by DPCs and has a potential role in repairing injured pulp tissues. FA may enhance oral lesion healing by promoting the proliferation and regeneration of oral mucosal cells. Future research on the use of FA in enhancing healing on the oral mucosal cells by inducing the expression of different cytokines that regulate molecules involved in cellular adhesion and extracellular matrix (ECM) formation is recommended for the effective treatment of severe and recalcitrant oral mucosal diseases.

Conclusion

FAO/FAS 0.1% is effective in the treatment of OLP, OLDR, oral pemphigus, and HAEM. FAO/FAS 0.1% rapidly reduces pain and inflammation. This topical steroid is low-cost (2 US$/5 gm pack) with no serious side-effects other than easily treated pseudomembranous candidiasis. Moreover, FAO/FAS 0.1% was safe when used in treating patients with multiple or various systemic diseases and a pregnant patient.

Acknowledgements

I would like to thank the Oral Medicine and Oral Pathology staff for their assistance. The Research Unit in Oral Diseases, Faculty of Dentistry, Chulalongkorn University is acknowledged for their long-term support. My special thanks are extended to Dr. Kevin Tompkins for the English language revision of this manuscript.

References

1. Liu C, Zhou Z, Liu G, Wang Q, Chen J, Wang L, et al. Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. Am J Med. 2012. Mar;125(3):292–301. 10.1016/j.amjmed.2011.09.011 [PubMed] [Cross Ref]
2. Thongprasom K, Dhanuthai K. Review of steroids in the treatment of oral lichen planus. J Oral Sci. 2008. Dec;50(4):377–85. 10.2334/josnusd.50.377 [PubMed] [Cross Ref]
3. Lodi G, Carrozzo M, Furness S, Thongprasom K. Interventions for treating oral lichen planus: a systematic review. Br J Dermatol. 2012. May;166(5):938–47. 10.1111/j.1365-2133.2012.10821.x [PubMed] [Cross Ref]
4. Thongprasom K, Sessririsombat S, Singkharotai K, Vathanasanti A, Subbalek K. Topical steroids and CO2 laser in the treatment of refractory oral lichenoid drug reaction and lichenoid contact lesion: a case report. Acta Stomatol Croat. 2014. Sep;48(3):224–9. 10.15644/asc48/3/7 [PMC free article] [PubMed] [Cross Ref]
5. Thongprasom K, Korkij W. Fluocinolone acetonide 0.1% solution and prednisolone in the treatment of oral pemphigus: 12-year follow-up. East J Med. 2002;7(2):47.
6. Thongprasom K, Suvanpiyasiri C, Sriwongsa SD, Iamaroon A, Korkij W, Lohwongwatana B, et al. Nickel- induced pemphigus vulgaris- like lesion. Acta Stomatol Croat. 2011;45(3):202–8.
7. Thongprasom K, Prasongtanskul S, Fongkhum A, Iamaroon A. Pemphigus, discoid lupus erythematosus, and dermatomyositis during an 8-year follow-up period: A case report. J Oral Sci. 2013. Sept;55(3):255–8. 10.2334/josnusd.55.255 [PubMed] [Cross Ref]
8. Carrozzo M, Carbone M, Broccoletti R, Garzino-Demo P, Gandolfo S. Therapeutic management of mucous membrane pemphigoid. Report of 11 cases. Minerva Stomatol. 1997. Oct;46(10):553–9. [PubMed]
9. Thongprasom K. Treatment of a Pregnant Patient with Herpes Associated Erythema Multiforme (HAEM): A case report. Acta Stomatol Croat. 2016. Sep;50(3):265–8. 10.15644/asc50/3/10 [PMC free article] [PubMed] [Cross Ref]
10. Mills JS, Bowers A, Djerassi C, Ringold HJ. Steroids CXXXVII. Synthesis of a New Class of Potent Cortical Hormones. 6α,9α-Difluoro-16α-Hydroxyprednisolone and its Acetonide. J Am Chem Soc. 1960;80:3399–404. 10.1021/ja01498a041 [Cross Ref]
11. MeSH Browser [database on the Internet]. FLUOCINOLONE ACETONIDE. Available from http://pubchem.ncbi.nlm.nih.gov/compound/fluocinolone acetonide
12. Thongprasom K. Milestone of Oral Medicine in Thailand: Faculty of Dentistry Chulalongkorn University Perspective. J Dent Assoc Thai. 2015. Jan;65(1):1–10.
13. Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C. Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up. J Oral Pathol Med. 2003. Jul;32(6):315–22. 10.1034/j.1600-0714.2003.00130.x [PubMed] [Cross Ref]
14. Thongprasom K, Dhanuthai K, Sarideechaigul W, Chaiyarit P, Chaimusig M. Expression of TNF–α in oral lichen planus treated with fluocinolone acetonide 0.1%. J Oral Pathol Med. 2006. Dec;35(3):161–6. 10.1111/j.1600-0714.2006.00392.x [PubMed] [Cross Ref]
15. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus; report of an international consensus meeting-Part 2. Management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005. Aug;100(2):164–78. 10.1016/j.tripleo.2004.06.076 [PubMed] [Cross Ref]
16. Bagán VJ, Thongprasom K, Scully C. Adverse oral reactions associated with the COX-2 inhibitor Rofecoxib. Oral Dis. 2004. Nov;10(6):401–3. 10.1111/j.1601-0825.2004.01024.x [PubMed] [Cross Ref]
17. Nalamliang N, Tangnuntachai N, Thongprasom K. Medications in Thai patients with oral lichen planus, oral lichenoid drug reaction and glossitis. IJEDS. 2014. July-December;3(2):73–6. 10.5005/jp-journals-10029-1075 [Cross Ref]
18. Iamaroon A, Boonyawong P, Klanrit P, Prasongtunskul S, Thongprasom K. Characterization of oral pemphigus vulgaris in Thai patients. J Oral Sci. 2006. Mar;48(1):43–6. 10.2334/josnusd.48.43 [PubMed] [Cross Ref]
19. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med. 1992. Nov;21(10):456–8. 10.1111/j.1600-0714.1992.tb00974.x [PubMed] [Cross Ref]
20. Varoni EM, Molteni A, Sardella A, Carrassi A, Di Candia D, Gigli F, et al. Pharmacokinetics study about topical clobetasol on oral mucosa. J Oral Pathol Med. 2012. Mar;41(3):255–60. 10.1111/j.1600-0714.2011.01087.x [PubMed] [Cross Ref]
21. Decani S, Federighi V, Baruzzi E, Sardella A, Lodi G. Iatrogenic Cushing’s syndrome and topical steroid therapy: case series a review of the literature. J Dermatolog Treat. 2014. Dec;25(6):495–500. 10.3109/09546634.2012.755252 [PubMed] [Cross Ref]
22. Arirachakaran P, Hanvanich M, Kuysakorn P, Thongprasom K. Antiretroviral Drug Associated Oral Lichenoid Reaction in HIV Patient. Int J Dent. 2010;2010:291072. 10.1155/2010/291072 [PMC free article] [PubMed] [Cross Ref]
23. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus; report of an international consensus meeting - Part 1. Viral infections and aetiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005. July;100(1):40–51. 10.1016/j.tripleo.2004.06.077 [PubMed] [Cross Ref]
24. Yuan A, Woo SB. Adverse drug events in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015. Jan;119(1):35–47. 10.1016/j.oooo.2014.09.009 [PubMed] [Cross Ref]
25. Fricain JC, Sibaud V, Campana F. S. Lepreux S, Taıeb A. Mucosal Pigmentation after Oral Lichen planus Treatment with Topical Tacrolimus. Dermatology. 2005;210(3):229–32. 10.1159/000083516 [PubMed] [Cross Ref]
26. Hara ES, Ono M, Pham HT, Sonoyama W, Kubota S, Takigawa M, et al. Fluocinolone Acetonide is a Potent Synergistic Factor of TGF-β3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration. J Bone Miner Res. 2015. Sep;30(9):1585–96. 10.1002/jbmr.2502 [PMC free article] [PubMed] [Cross Ref]
27. Liu Z, Jiang T, Wang Y, Wang X. Fluocinolone acetonide promotes the proliferation and mineralization of dental pulp cells. J Endod. 2013. Feb;39(2):217–22. 10.1016/j.joen.2012.09.012 [PubMed] [Cross Ref]
28. Covas DT, Panepucci RA, Fontes AM, Silva WA, Jr, Orellana MD, Freitas MC, et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol. 2008. May;36(5):642–54. 10.1016/j.exphem.2007.12.015 [PubMed] [Cross Ref]
29. Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, et al. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol. 2008. Aug;36(8):1035–46. 10.1016/j.exphem.2008.03.004 [PubMed] [Cross Ref]
30. Russell KC, Phinney DG, Lacey MR, Barrilleaux BL, Meyertholen KE, O’Connor KC, et al. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells. 2010. Apr;28(4):788–98. 10.1002/stem.312 [PubMed] [Cross Ref]

Articles from Acta Stomatologica Croatica are provided here courtesy of University of Zagreb: School of Dental Medicine